SUMMARY
Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY FINDINGS
Essential resource for top-line data and analysis covering the Netherlands generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
REASONS TO BUY
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Dutch generics market is expected to generate total revenues of $1.0bn in 2016, representing a compound annual growth rate (CAGR) of 1.8% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 2.4% between 2012 and 2016, to reach a total of 73.5% of total pharma volume in 2016.
The Netherlands has one of the highest generic volume shares in Europe, but continues to grow as cost savings appeal to private and public healthcare providers.
Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY FINDINGS
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the Netherlands
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the Netherlands
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Netherlands generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
REASONS TO BUY
- What was the size of the Netherlands generics market by value in 2016?
- What will be the size of the Netherlands generics market in 2021?
- What factors are affecting the strength of competition in the Netherlands generics market?
- How has the market performed over the last five years?
- How large is the Netherlands's generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Dutch generics market is expected to generate total revenues of $1.0bn in 2016, representing a compound annual growth rate (CAGR) of 1.8% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 2.4% between 2012 and 2016, to reach a total of 73.5% of total pharma volume in 2016.
The Netherlands has one of the highest generic volume shares in Europe, but continues to grow as cost savings appeal to private and public healthcare providers.
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan Inc.
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan Inc.
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
LIST OF TABLES
Table 1: Netherlands generics market value: $ billion, 2012-16(e)
Table 2: Netherlands generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Netherlands generics market geography segmentation: $ billion, 2016(e)
Table 4: Netherlands generics market value forecast: $ billion, 2016-21
Table 5: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (€)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: Netherlands size of population (million), 2012-16
Table 18: Netherlands gdp (constant 2005 prices, $ billion), 2012-16
Table 19: Netherlands gdp (current prices, $ billion), 2012-16
Table 20: Netherlands inflation, 2012-16
Table 21: Netherlands consumer price index (absolute), 2012-16
Table 22: Netherlands exchange rate, 2012-16
Table 1: Netherlands generics market value: $ billion, 2012-16(e)
Table 2: Netherlands generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Netherlands generics market geography segmentation: $ billion, 2016(e)
Table 4: Netherlands generics market value forecast: $ billion, 2016-21
Table 5: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (€)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: Netherlands size of population (million), 2012-16
Table 18: Netherlands gdp (constant 2005 prices, $ billion), 2012-16
Table 19: Netherlands gdp (current prices, $ billion), 2012-16
Table 20: Netherlands inflation, 2012-16
Table 21: Netherlands consumer price index (absolute), 2012-16
Table 22: Netherlands exchange rate, 2012-16
LIST OF FIGURES
Figure 1: Netherlands generics market value: $ billion, 2012-16(e)
Figure 2: Netherlands generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Netherlands generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Netherlands generics market value forecast: $ billion, 2016-21
Figure 5: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in the Netherlands, 2016
Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2016
Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016
Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2016
Figure 12: Mylan Inc.: revenues and profitability
Figure 13: Mylan Inc.: assets and liabilities
Figure 14: Sanofi SA: revenues and profitability
Figure 15: Sanofi SA: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities
COMPANIES MENTIONED
Mylan Inc.
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Skip to top
Figure 1: Netherlands generics market value: $ billion, 2012-16(e)
Figure 2: Netherlands generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Netherlands generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Netherlands generics market value forecast: $ billion, 2016-21
Figure 5: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in the Netherlands, 2016
Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2016
Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016
Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2016
Figure 12: Mylan Inc.: revenues and profitability
Figure 13: Mylan Inc.: assets and liabilities
Figure 14: Sanofi SA: revenues and profitability
Figure 15: Sanofi SA: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities
COMPANIES MENTIONED
Mylan Inc.
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Car Aftermarket Components - OES -v- Generic Suppliers Global Report
US$ 950.00
Jul, 2017 · 405 pages
